Martin Mackay

Type: Person
Name: Martin Mackay
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

Alexion Pharmaceuticals : Asfotase Alfa Secures Orphan Drug Designation in Japan

Alexion Pharmaceuticals recently reported that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to asfotase alfa for the treatment of patients with hypophosphatasia (HPP), a genetic, chronic and progressive ... [Published 4 Traders - Sep 20 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function

--Data from Phase 2 Extension Studies Presented at ESPE Meeting--DUBLIN, Ireland--(BUSINESS WIRE)--September 19, 2014--Alexion Pharmaceuticals today announced that researchers presented data from the open-label extension phases of two Phase 2 studies ... [Published Scottrade - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Alexion announces encouraging data from hypophosphatasia analysis

Alexion Pharmaceuticals, Inc. has announced encouraging data from an integrated analysis of survival from two open-label, Phase II studies of asfotase alfa in pediatric patients with hypophosphatasia, or HPP, compared with data from a retrospective natural ... [Published Individual.com - Sep 17 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Alexion receives orphan drug designation from MHLW for hypophosphatasia drug

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare, or MHLW, for asfotase alfa for the treatment of patients with hypophosphatasia, or HPP, a genetic, chronic ... [Published Individual.com - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Asfotase Alfa Gets Orphan Drug Designation in Japan

Alexion Pharmaceuticals said that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to asfotase alfa for the treatment of patients with hypophosphatasia (HPP), a genetic, chronic and progressive ultra-rare ... [Published Individual.com - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Alexion’s Asfotase Alfa For HPP Receives Orphan Status In Japan

By Estel Grace MasangkayAlexion Pharmaceuticals reported that it has received Orphan Drug Designation from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for its asfotase alfa as treatment for patients with hypophosphatasia (HPP).Asfotase ... [Published Bioresearch Online - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function DGF after Kidney Transplantation

By a News Reporter-Staff News Editor at Biotech Week Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced the initiation of dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab (Soliris) ... [Published Pharmacy Choice - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Asfotase Alfa Granted Orphan Drug Designation in Japan

. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to asfotase alfa for the treatment of patients with hypophosphatasia (HPP), a genetic, chronic and progressive ultra-rare ... [Published Pettinga Financial Advisors - Sep 08 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 1 reports

Alexion Launches Eculizumab Trial In Kidney Transplant DGF

By Estel Grace MasangkayAlexion announced that it has started dosing in its clinical trial evaluating eculizumab for the prevention of delayed graft function (DGF). The trial involves adult patients who have undergone kidney transplantation and who are ... [Published Bioresearch Online - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 1 reports

Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the initiation of dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab (Soliris) for the prevention of delayed graft function ... [Published FinanzNachrichten.de - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

The Case for Orphan Drugs

Neglected by the pharmaceutical industry before the Orphan Drug Act of 1983, rare diseases are now front and center in pharma R&D. Approximately one-third of all new medicines approved by the FDA in the past 5 years were developed for the treatment of ... [Published Drug Discovery and Development - Aug 22 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Network key to supply

Supply chain: The head of a new NSW grain port said the industry needs to leverage off existing infrastructure and improve rail and road capacity to reap benefits. Source: News Corp AustraliaTHERE are simple ways to ­improve the nation’s grain supply ... [Published Weekly Times Now - Aug 20 2014]

Quotes

"hpp is a devastating disease for patients and families and there are currently no approved treatment options" said Martin Mackay , Ph D , Executive Vice President, Global Head of R&D at Alexion...
"paediatric patients with severe hpp face significant challenges related to growth, development and physical function" said Martin Mackay, Ph D , Executive Vice President and Global Head of R&D at Alexion...
...and there are currently no approved treatment options," said Martin Mackay, Ph D , Executive vice president, Global Head of R&D at Alexion. "the orphan drug designation granted for asfotase alfa undescores the significant need for an effective treatment option for japanese patients suffering from this severe, ultra-rare disorder."
...7 Uncontrolled complement activation following IRI is believed to play a major role in the development of DGF.8-11 "delayed graft function is a serious and significant complication to successful kidney transplantation, which can be life-threatening due to the risk of losing the transplanted organ" said Martin Mackay, Ph D , executive vice president and global head of R&D at Alexion...

More Content

All (15) | News (15) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Alexion Pharmaceuticals : Asfotase Alfa Secures... [Published 4 Traders - Sep 20 2014]
Paediatric Patients with Hypophosphatasia Recei... [Published Scottrade - Sep 19 2014]
Alexion announces encouraging data from hypopho... [Published Individual.com - Sep 17 2014]
Alexion receives orphan drug designation from M... [Published Individual.com - Sep 12 2014]
Asfotase Alfa Gets Orphan Drug Designation in J... [Published Individual.com - Sep 11 2014]
Alexion’s Asfotase Alfa For HPP Receives Orphan... [Published Bioresearch Online - Sep 10 2014]
Alexion Initiates Multinational Registration Tr... [Published Pharmacy Choice - Sep 10 2014]
Asfotase Alfa Granted Orphan Drug Designation i... [Published Pettinga Financial Advisors - Sep 08 2014]
Alexion Launches Eculizumab Trial In Kidney Tra... [Published Bioresearch Online - Aug 27 2014]
Alexion Initiates Multinational Registration Tr... [Published FinanzNachrichten.de - Aug 25 2014]
The Case for Orphan Drugs [Published Drug Discovery and Development - Aug 22 2014]
Network key to supply [Published Weekly Times Now - Aug 20 2014]
Prothelia, University of Nevada sign agreements... [Published PharmaBiz - Feb 15 2014]
Prothelia and the University of Nevada, Reno En... [Published PR Newswire - Feb 13 2014]
US FDA grants Alexion' Soliris orphan drug stat... [Published Pharmaceutical Business Review - Jan 22 2014]
1
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.